secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001558370-25-008711
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Phase 2 EMBRAZE trial shows 54.9% lean mass preservation with apitegromab plus tirzepatide (p=0.001)
--------------------------------------------------------------------------------

- Primary endpoint met: apitegromab + tirzepatide preserved 54.9% of lean mass (p=0.001) vs tirzepatide alone over 24 weeks.
- Patients on combination lost 18.8 lbs fat mass vs 17.7 lbs for tirzepatide alone; total weight loss 12.3% vs 13.4%.
- Quality of weight loss improved: 85% fat / 15% lean mass loss with combination vs 70% fat / 30% lean with tirzepatide alone.
- Apitegromab well tolerated; no SAEs or discontinuations related to apitegromab, consistent with prior studies.
- Company plans to file IND for next-gen SRK-439 in H2 2025; conference call today at 8 AM EDT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837025008711/0001558370-25-008711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837025008711/srrk-20250618x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer